Variable | All patients with available data, n/n PA negative/PA positive | PA negative | PA positive | P-value |
---|---|---|---|---|
Demographics | ||||
Sex (male), n (%) | 334/9 | 173 (51.8) | 4 (44.4) | 0.744 |
Age, years, mean (SD) | 334/9 | 53.4 (11.2) | 54.3 (9.2) | 0.763 |
BMI, kg/m2, n (%) | 213/9 | 0.498 | ||
≤25 | 47 (22.1) | 1 (11.1) | ||
>25–≤30 | 96 (45.1) | 6 (66.7) | ||
>30 | 70 (32.9) | 2 (22.2) | ||
Smoking status, n (%) | 163/9 | 0.404 | ||
Current | 36 (22.1) | 2 (22.2) | ||
Former | 55 (33.7) | 1 (11.1) | ||
Never | 72 (44.2) | 6 (66.7) | ||
Blood pressure, mean (SD) | ||||
Systolic BP, mmHg | 332/9 | 163.8 (13.4) | 158.6 (10.2) | 0.174 |
Diastolic BP, mmHg | 329/9 | 96.3 (9.9) | 95.3 (9.1) | 0.747 |
ABPM, mmHg | 47/2 | 154.2 (15.7) | 166.5 (9.2) | 0.282 |
ABPMday, mmHg | 42/1 | 159.3 (15.6) | 161.0 (−) | – |
Home BP, mmHg | 2/0 | 160.0 (0) | – | – |
Heart rate, beats/minute | 192/7 | 75.2 (12.6) | 68.6 (12.8) | 0.224 |
Biochemical parameters | ||||
Serum potassium, mmol/l, mean (SD) | 332/9 | 4.43 (0.33) | 4.11 (0.26) | 0.006 |
Serum sodium, mmol/l, mean (SD) | 332/9 | 141.7 (2.0) | 141.7 (2.6) | 0.951 |
Serum creatinine, µmol/l, mean (SD) | 332/9 | 78.8 (14.6) | 75.8 (13.1) | 0.510 |
Plasma aldosterone, pmol/l, mean (SD) | 334/9 | 360.9 (220.5) | 668.4 (118.1) | <0.001 |
Renin, pmol/l, median (IQR) | 334/9 | 0.78 (0.58 to 1.33) | 0.48 (0.34 to 0.68) | 0.003 |
ARR, pmol/mU, mean (SD) | 334/9 | 29.8 (22.8) | 105.3 (48.6) | 0.002 |
Serum glucose, mmol/l, mean (SD) | 301/9 | 5.4 (1.0) | 5.4 (0.5) | 0.750 |
Cardiovascular morbidity, n (%) | ||||
OSAS | 334/9 | 5 (1.5) | 0 | 1.000 |
Atrial fibrillation | 334/9 | 2 (0.6) | 0 | 1.000 |
Stroke | 334/9 | 2 (0.6) | 0 | 1.000 |
Myocardial infarction | 334/9 | 2 (0.6) | 0 | 1.000 |
ABPM = ambulatory blood pressure monitoring. ARR = aldosterone-to-renin ratio. BMI = body mass index. Home BP = home systolic blood pressure. IQR = interquartile range. OSAS = obstructive sleep apnoea syndrome. PA = primary aldosteronism. SD = standard deviation.